Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Breadcrumb

  1. Emmes Group

Interim results of the International Multi-Center Trial of Islet Transplantation Using the Edmonton Protocol in Patients with Type 1 Diabetes

Go back to Resources

Interim results of the International Multi-Center Trial of Islet Transplantation Using the Edmonton Protocol in Patients with Type 1 Diabetes

Authors:

Location:

Go back to Resources

Induction of human T-Cell-Mediated immune responses after primary and secondary smallpox vaccination

Go back to Resources

Induction of human T-Cell-Mediated immune responses after primary and secondary smallpox vaccination

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Evaluation of intravenous immunoglobulin (IVIG) as an agent to lower allosensitization and improve transplantation in highly-sensitized adult ESRD patients: report of the NIH IG02 trial

Go back to Resources

Evaluation of intravenous immunoglobulin (IVIG) as an agent to lower allosensitization and improve transplantation in highly-sensitized adult ESRD patients: report of the NIH IG02 trial

Authors:

Secondary:

Pagination:

Go back to Resources

Estimated reates of progression to advanced AMD and vision loss by baseline maculopathy status: Results from the Age-Related Eye Disease Study

Go back to Resources

Estimated reates of progression to advanced AMD and vision loss by baseline maculopathy status: Results from the Age-Related Eye Disease Study

Authors:

Location:

Go back to Resources

Electronic Monitoring of Data Quality Using the "Contradiction Density"

Go back to Resources

Electronic Monitoring of Data Quality Using the "Contradiction Density"

Authors:

Location:

Go back to Resources

Effect of antioxidant supplementation on blood plasma thiol redox status in AREDS participants with early to late ARMD

Go back to Resources

Effect of antioxidant supplementation on blood plasma thiol redox status in AREDS participants with early to late ARMD

Authors:

Location:

Go back to Resources

Dose-dependent neutralizing-antibody responses to vaccinia

Go back to Resources

Dose-dependent neutralizing-antibody responses to vaccinia

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Results of the Cord Blood Transplantation Study (COBLT): Clinical Outcomes of Unrelated Donor Umbilical Cord Blood Transplantation in Pediatric Patients with Inborn Errors of Metabolism

Go back to Resources

Results of the Cord Blood Transplantation Study (COBLT): Clinical Outcomes of Unrelated Donor Umbilical Cord Blood Transplantation in Pediatric Patients with Inborn Errors of Metabolism

Authors:

Secondary:

Location:

Go back to Resources

Results of the Cord Blood Transplantation Study (COBLT) Unrelated Donor Banking Program

Go back to Resources

Results of the Cord Blood Transplantation Study (COBLT) Unrelated Donor Banking Program

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Results of an ELISPOT Proficiency Panel Conducted in 11 Laboratories Participating in International Human Immunodeficiency Virus Type 1 Vaccine Trials

Go back to Resources

Results of an ELISPOT Proficiency Panel Conducted in 11 Laboratories Participating in International Human Immunodeficiency Virus Type 1 Vaccine Trials

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 146
  • Page 147
  • Page 148
  • Page 149
  • Current page 150
  • Page 151
  • Page 152
  • Page 153
  • Page 154
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions